References
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: 239–45.
- Back DJ. Re: ‘Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir’. Br J Clin Pharmacol 2000; 50:85.
- Shabsigh R, Seftel AD, Rosen RC, Porst H, Ahuja S, Deeley MC, . Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology 2006;68:689–96.
- Cialis (tadalafil) full prescribing information. Indianapolis, IN: Eli-Lilly; 2007. Available at: http://pi.lilly.com/us/cialis-pi.pdf (accessed date is 2007).
- Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4–9.
- Galatti L, Fioravanti A, Salvo F, Polimeni G, Giustini SE. Interaction between tadalafil and itraconazole. Ann Pharmacother 2005;39:200.
- Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50: 99–107.
- National Library of Medicine. DailyMed. Current medication information. Bethesda, MD: US NLM; 2010. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo (access date is 2007). page has moved to http://0-dailymed.nlm.nih.gov.www.elgar.govt.nz/dailymed/drugInfo.cfm?id=21906. date of publication is 2010.